Advertisement
UK markets close in 6 hours
  • FTSE 100

    8,076.73
    +31.92 (+0.40%)
     
  • FTSE 250

    19,786.45
    -13.27 (-0.07%)
     
  • AIM

    754.69
    -0.18 (-0.02%)
     
  • GBP/EUR

    1.1630
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.2434
    -0.0019 (-0.15%)
     
  • Bitcoin GBP

    53,438.06
    +147.07 (+0.28%)
     
  • CMC Crypto 200

    1,432.70
    +8.60 (+0.60%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    82.88
    -0.48 (-0.58%)
     
  • GOLD FUTURES

    2,327.90
    -14.20 (-0.61%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • DAX

    18,177.33
    +39.68 (+0.22%)
     
  • CAC 40

    8,120.06
    +14.28 (+0.18%)
     

Have Gilead's Gains Evaporated in the Coronavirus Treatment Race?

Have Gilead's Gains Evaporated in the Coronavirus Treatment Race?

Gilead Sciences (NASDAQ: GILD) started the year strong. As a result, while the rest of the stock market slid, Gilead did just the opposite. To make matters worse, the World Health Organization (WHO) recently advised against using remdesivir as a treatment for COVID-19.